OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.62 USD
+0.01 (0.62%)
Updated Feb 6, 2025 04:00 PM ET
After-Market: $1.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Company Summary
Headquartered in Miami, Florida, OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico.
The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases
.
The company’s pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (launched in November 2016) and VARUBI for chemotherapy induced nausea and vomiting.
OPKO Health has a ...
Company Summary
Headquartered in Miami, Florida, OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico.
The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases
.
The company’s pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (launched in November 2016) and VARUBI for chemotherapy induced nausea and vomiting.
OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.
The company operates through three revenue segments — Revenues from services, revenues from products and revenues from transfer of intellectual property.
2023 at a Glance
Net revenues in 2023 totaled $863.5 million, down 14% over 2022.
The Florida-based diagnostics and pharmaceuticals company reports through three major segments — Services revenues (59.7% of total FY23 revenue, down 31.8% over FY22), products revenues (19.4%, up 17.2%), and transfer of intellectual property and other revenues (20.9%, up 70.9%).
General Information
OPKO Health, Inc
4400 BISCAYNE BLVD.
MIAMI, FL 33137
Phone: 305-575-4100
Fax: 305-575-6015
Web: http://www.opko.com
Email: ybriggs@allianceadvisors.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 12/31/2024 |
Exp Earnings Date | 2/25/2025 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.11 |
Current Year EPS Consensus Estimate | -0.25 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 2/25/2025 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 1.61 |
52 Week High | 1.76 |
52 Week Low | 0.86 |
Beta | 1.63 |
20 Day Moving Average | 2,717,826.50 |
Target Price Consensus | 3.05 |
4 Week | 9.46 |
12 Week | 0.00 |
YTD | 10.20 |
4 Week | 6.48 |
12 Week | -2.21 |
YTD | 6.27 |
Shares Outstanding (millions) | 682.48 |
Market Capitalization (millions) | 1,105.62 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year (Q0/Q-4) | 127.27% |
vs. Previous Quarter (Q0/Q-1) | 400.00% |
vs. Previous Year (Q0/Q-4) | -2.80% |
vs. Previous Quarter (Q0/Q-1) | -4.72% |
Price/Book | 0.81 |
Price/Cash Flow | NA |
Price / Sales | 1.55 |
12/31/24 | Pending Next EPS Report |
9/30/24 | -9.76 |
6/30/24 | -17.67 |
12/31/24 | Pending Next EPS Report |
9/30/24 | -6.46 |
6/30/24 | -12.07 |
12/31/24 | Pending Next EPS Report |
9/30/24 | 2.97 |
6/30/24 | 1.63 |
12/31/24 | Pending Next EPS Report |
9/30/24 | 2.69 |
6/30/24 | 1.36 |
12/31/24 | Pending Next EPS Report |
9/30/24 | -18.65 |
6/30/24 | -33.79 |
12/31/24 | Pending Next EPS Report |
9/30/24 | -18.65 |
6/30/24 | -33.79 |
12/31/24 | Pending Next EPS Report |
9/30/24 | -16.57 |
6/30/24 | -34.15 |
12/31/24 | Pending Next EPS Report |
9/30/24 | 2.01 |
6/30/24 | 2.00 |
12/31/24 | Pending Next EPS Report |
9/30/24 | 8.71 |
6/30/24 | 8.34 |
12/31/24 | Pending Next EPS Report |
9/30/24 | 0.30 |
6/30/24 | 0.13 |
12/31/24 | Pending Next EPS Report |
9/30/24 | 23.20 |
6/30/24 | 11.20 |